Quick answer: Finished peptide vial orders always require producing more vials than are delivered, because QC testing, retain samples, and reconstitution verification consume finished units. Experienced buyers therefore specify the delivered quantity separately from the production quantity, and define the QC sampling scope, overage, and its cost before production begins.
In other words: a 120-vial order is never a 120-vial production run. Most of the tests that qualify a batch of finished lyophilized vials are destructive — the vial that is tested cannot be shipped — and retained samples are held rather than delivered. Neither side is being difficult when this shows up in a specification or a quotation. Both are describing how finished-product testing actually works, and the only real failure is leaving the arithmetic undefined until after the deposit.
This guide is written for procurement and QA teams specifying finished-vial peptide projects. It is a specification and process reference. It does not establish that any material is sterile, endotoxin-controlled, pharmaceutical grade, suitable for injection, or approved for human use, and it does not provide dosing or medical guidance.
1. The clause sophisticated buyers write — and why it is reasonable
A specification we see from experienced buyers reads, in substance:
All ordered quantities are final delivery quantities. Any vials used for testing, retained samples, or reconstitution verification must be produced in addition and must not be deducted from the delivered quantity.
A team placing its first finished-vial order might read that as aggressive. It is the opposite: it is the clause of someone who knows the tests are real. A procurement manager who orders 20 vials of a peptide and receives 16 — because 4 were consumed by the very testing that produced the COA — has a legitimate complaint only if nobody defined the arithmetic in advance. The clause removes the ambiguity in the buyer's favor; the supplier's correct response is not to resist it but to price it.
The mirror-image failure also exists: a manufacturer who quotes 20 vials, tests nothing, and ships 20 vials has delivered a full count of unqualified units. A batch document package with no consumed vials behind it is a batch document package to question.
2. Which steps consume finished vials
The exact sampling plan depends on the batch size, the agreed test scope, and the applicable procedures. What does not change is the direction: each of the following uses up finished units.
The path from production to delivery looks like this:
| Stage | What happens to the vials |
|---|---|
| Batch produced | Delivered quantity plus QC overage, filled and lyophilized as one batch — every vial identical. |
| → QC sampling | Consumed by testing, never shipped: finished-product analytical testing, content verification per the agreed sampling plan, sterility and endotoxin testing where specified, reconstitution verification. |
| → Retain samples | Held by the manufacturer for a defined period — not shipped. |
| → Delivered quantity | What the buyer receives. |
| Step | What it does | Why it consumes vials |
|---|---|---|
| Finished-product analytical testing | Identity, purity, and content verified on the finished vial, not only on the bulk material. | The vial is opened and the material is dissolved and injected. It cannot be resealed or shipped. |
| Content verification per the agreed sampling plan | Confirms that sampled vials contain what the label states, not just that the batch average is right. | Units are sampled and tested according to the agreed sampling plan, which varies with the batch size and the applicable procedure and regulatory framework. |
| Sterility and endotoxin testing | Performed where the project specifies these attributes. | Test articles are consumed by the assay. |
| Reconstitution verification | Confirms dissolution behavior of the actual batch under stated conditions. | Each verified vial is reconstituted and observed — destructive by definition. |
| Retain samples | Units from the batch kept by the manufacturer for a defined period. Retain policies vary between manufacturers and regulatory frameworks, so the count and holding period are project-defined. | Not consumed on day one, but not deliverable either: they exist to answer future questions about this batch. |
Two consequences for the specification:
- Overage is project-defined, not a universal constant. The number of additional vials depends on which of these steps are in scope and on the sampling required for the batch size. A supplier should state the number for the actual project rather than quote a folk figure, and WUMO confirms QC vial consumption per project at quotation.
- Testing on the finished vial is not redundant with testing the bulk material. A bulk assay describes the material before filling; finished-vial testing covers what filling, lyophilization, and sealing did to it. The two answer different questions — the same layered logic as net peptide content versus the per-vial claim.
3. Who pays for the QC vials
The QC vials are made of the same peptide, the same excipients, the same fill and lyophilization time as the delivered ones. Their cost is real, and there are only two honest places for it: inside the unit price, or as a stated separate line. Both are legitimate. What is not legitimate is silence, because silent overage cost surfaces later as one of three bad outcomes — a renegotiation after the deposit, a quietly reduced test scope, or vials deducted from the delivery after all.
A worked example makes the difference concrete. The numbers are chosen for arithmetic clarity only — they are not a typical or recommended sampling figure, which is always project-defined:
- Overage defined upfront. A procurement team orders 100 vials as net delivered quantity. The quotation states that, say, 4 additional vials will be produced for QC and retains. The manufacturer fills 104, consumes and holds 4, and the buyer receives 100 tested vials. Everyone's arithmetic was agreed before the batch existed.
- Overage never discussed. The same order, but the supplier fills exactly 100. Either the required testing consumes vials and the buyer receives 96 with an explanation after the fact — or, worse, nothing is consumed, the buyer receives all 100, and the batch document package has no tested finished vials behind it.
The second path is cheaper on the quotation and more expensive everywhere else.
Procurement teams comparing two finished-vial quotations should therefore normalize them the same way they normalize labeling basis and salt form: a price that includes stated QC consumption and retains, and a price that is silent about both, are not two prices for the same thing.
4. More QC vials do not automatically mean better quality
A natural conclusion from the previous sections would be that the supplier consuming the most vials is the most rigorous one. That conclusion is wrong, and it is worth stating plainly because it leads procurement teams to compare the wrong number.
QC consumption is an input. What actually determines whether the resulting documents mean anything is the quality system behind the sampling:
- The sampling plan — how test units are selected and justified for this batch size, not merely how many there are.
- The analytical methods — whether the tests behind each result are appropriate and consistently applied, with the method stated on the document.
- Traceability and batch linkage — whether every result can be tied to the specific lot being shipped, the theme running through the whole documentation review guide.
- Documentation — whether the sampling scope, results, and retain policy are written down where the buyer can hold the supplier to them.
Ten vials consumed under an undocumented, untraceable routine are worth less than three consumed under a defined plan with batch-linked results. Quality managers evaluating suppliers should ask to see the sampling plan and the linkage — and treat the vial count as a consequence of that plan, not as a score.
5. Anatomy of a reconstitution acceptance protocol
Reconstitution behavior is where finished-vial quality becomes visible without an instrument, and experienced procurement and QA teams increasingly specify it as a formal acceptance test rather than a courtesy photo. A well-written protocol — and we have received well-written ones — defines all of the following:
| Element | What a complete specification states |
|---|---|
| Test articles | How many vials, drawn from the actual shipping batch, not from an earlier or representative batch. |
| Diluent and volume | The reconstitution medium and the exact volume added per vial. |
| Handling | How dissolution is assisted — for example gentle swirling, with sonication or heating either permitted or excluded. |
| Time criterion | The time within which complete dissolution must occur. |
| Appearance criteria | What the solution must and must not show — turbidity, gel formation, stringiness, clumping, crystallization, visible particles. |
| Observation schedule | Time points after reconstitution (for example spanning hours to days) and the storage condition between them. |
| Documentation | Recorded results and photographs at each time point, linked to the batch. |
Each row closes a gap that a bare "does it dissolve?" leaves open. A vial can dissolve completely but slowly; dissolve fast but haze over on day three under refrigeration; or pass everything on a demo batch and fail on the batch that ships. Batch linkage, time-course observation, and defined handling are what turn a photogenic moment into evidence.
What a supplier can honestly commit to — and when. A dissolution-time or day-seven-clarity criterion is a property of a specific formulation of a specific peptide, and the honest sequence is: run the buyer's protocol on the actual formulation first, then commit to the criteria the results support. WUMO's practice, when a buyer specifies a protocol like the one above, is to perform the test internally before confirming acceptance criteria — a commitment made before the first vial has been reconstituted is a marketing statement, not a test result. This is the same test-first position described in Why Lyophilized Peptide Cakes Collapse for appearance and pilot runs, and it costs a supplier nothing except the ability to over-promise.
Boundary. A reconstitution result — however well documented — establishes the observed dissolution behavior under the stated test conditions, and nothing else. It does not establish sterility, endotoxin status, isotonicity, compatibility with any route of administration, or readiness for human use.
6. What to write in the RFQ
| RFQ field | What to state |
|---|---|
| Net delivery clause | That ordered quantities are final delivered quantities, with QC, retain, and verification vials produced additionally. |
| QC sampling scope | Which finished-vial tests are in scope, and a request that the supplier state the resulting vial consumption per SKU for this batch size. |
| Overage cost treatment | Whether QC vial cost is inside the unit price or a separate stated line — either is acceptable, silence is not. |
| Retain samples | Whether retains are required, how many units, and for how long they are held. |
| Reconstitution protocol | The full protocol per the previous section, including batch linkage and photo documentation, and whether it is an acceptance criterion or an information-only test. |
| Commitment sequence | Whether acceptance criteria are to be confirmed after a supplier-run verification on the actual formulation. |
7. Red flags
None of these proves bad faith. Each is a question to close before a deposit.
- The quotation matches the delivered count exactly, with no mention of QC consumption, sampling, or retains.
- Delivered quantity arrives short, with testing offered as the explanation only after the fact.
- A dissolution-time guarantee is offered for a peptide and formulation the supplier has not yet run the protocol on.
- Reconstitution evidence comes from a different batch than the one shipped, or is undated and unlinked.
- Retain samples are "not applicable" for a supplier claiming batch accountability.
- The QC scope quietly shrinks between quotation and delivery without a corresponding document.
Frequently Asked Questions
Why does a supplier need to produce more vials than I ordered?
Because most finished-product tests are destructive. Vials used for finished-product analytical testing, content verification under the agreed sampling plan, sterility and endotoxin testing, and reconstitution verification are opened and consumed, and retained samples are held rather than shipped. If the delivered quantity is fixed, those units must be produced in addition to it.
How many extra vials does QC consume?
It is project-defined. The overage depends on which tests are in scope, the sampling the applicable procedure requires, and the batch size. Ask the supplier to state the number for your batch in the quotation rather than accept a generic figure — or silence.
Should QC vials be free?
The material and process cost of a QC vial is the same as a delivered vial, so the cost exists either way. Some suppliers absorb it in the unit price; some state it as a separate line. Both are legitimate as long as the treatment is stated at quotation. An unstated overage cost tends to resurface later as a renegotiation, a reduced test scope, or a shorted delivery.
What is a retain sample and why does the supplier keep it?
A retained sample is a set of units from the shipped batch that the manufacturer stores for a defined period. If a question arises about the batch later, the retain allows testing of the same lot under controlled custody. It is a sign of batch accountability, not of holding back product. Retain policies vary between manufacturers and regulatory frameworks, so the count and holding period should be stated per project rather than assumed.
Can buyers provide their own QC protocol?
Yes. Many experienced procurement and QA teams specify their own protocols — a reconstitution acceptance test with defined time points is a common example — and a capable supplier should be able to execute a reasonable buyer-authored protocol and document the results against it. The workable sequence is the same as elsewhere in this guide: the supplier runs the buyer's protocol on the actual formulation first, then confirms which acceptance criteria the results support, rather than signing up to numerical criteria before the first vial has been tested.
What should a reconstitution verification actually specify?
The number of vials and their batch linkage, the diluent and exact volume, the handling method, the time criterion for complete dissolution, the appearance criteria, the post-reconstitution observation schedule and storage condition, and the required records and photographs. A test missing the batch linkage or the time course is substantially weaker evidence.
Can a supplier guarantee my dissolution-time requirement upfront?
The honest sequence is test first, commit after. Dissolution behavior is a property of a specific formulation of a specific peptide, so a credible supplier runs the buyer's protocol on the actual formulation and then confirms the criteria the results support. A guarantee offered before the first vial has been reconstituted is a promise, not a result.
Does a passing reconstitution test mean the product is sterile or safe to use?
No. It establishes the observed dissolution behavior under the stated conditions — nothing more. Sterility, endotoxin status, and any suitability-for-use questions are separate attributes with their own tests and are not addressed by reconstitution behavior.
Is testing the finished vial redundant if the bulk material was already tested?
No. The bulk assay describes the material before filling; finished-vial testing covers the result of compounding, filling, lyophilization, and sealing. A batch document package that stops at the bulk material has not tested the product you receive.
Put the arithmetic in the specification
Before placing a finished-vial order, ask the supplier to clearly define:
- the QC sampling scope, and the vials it consumes for your batch size;
- the retain sample policy — how many units, held for how long;
- where the overage cost sits — inside the unit price or as a stated line;
- the reconstitution verification protocol, its batch linkage, and whether it is an acceptance criterion.
A supplier who can answer all four in the quotation is describing a controlled process. If you would like to discuss how WUMO structures these items for a specific project, we confirm QC vial consumption and reconstitution verification scope before issuing a formal quotation — and we run buyer-specified reconstitution protocols on the actual formulation before committing to acceptance criteria. For the wider document package these results sit inside, see the finished-vial sourcing guide.